Jump to content

Opioidergic: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
OAbot (talk | contribs)
Bots
441,761 edits
m Open access bot: doi added to citation with #oabot.
Citation bot (talk | contribs)
Bots
5,438,982 edits
Alter: issue. Add: s2cid. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:Neurotransmitters | via #UCB_Category
Line 9: Line 9:
* Ignavine<ref name="pmid27530869">{{cite journal |vauthors=Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y |title=Ignavine: a novel allosteric modulator of the μ opioid receptor |journal=Sci Rep |volume=6 |issue= |pages=31748 |date=August 2016 |pmid=27530869 |pmc=4987652 |doi=10.1038/srep31748 |url=}}</ref>
* Ignavine<ref name="pmid27530869">{{cite journal |vauthors=Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y |title=Ignavine: a novel allosteric modulator of the μ opioid receptor |journal=Sci Rep |volume=6 |issue= |pages=31748 |date=August 2016 |pmid=27530869 |pmc=4987652 |doi=10.1038/srep31748 |url=}}</ref>
* [[Oxytocin]]: μ-PAM<ref name="pmid29716811">{{cite journal |vauthors=Meguro Y, Miyano K, Hirayama S, et al |title=Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |journal=J. Pharmacol. Sci. |volume=137 |issue=1 |pages=67–75 |date=May 2018 |pmid=29716811 |doi=10.1016/j.jphs.2018.04.002 |url=|doi-access=free }}</ref>
* [[Oxytocin]]: μ-PAM<ref name="pmid29716811">{{cite journal |vauthors=Meguro Y, Miyano K, Hirayama S, et al |title=Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator |journal=J. Pharmacol. Sci. |volume=137 |issue=1 |pages=67–75 |date=May 2018 |pmid=29716811 |doi=10.1016/j.jphs.2018.04.002 |url=|doi-access=free }}</ref>
* δ-PAM (see reference)<ref name="pmid25901762">{{cite journal |vauthors=Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, Traynor JR, Gerritz SW, Alt A |title=Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor |journal=J. Med. Chem. |volume= 58|issue= |pages= 4220–9|year=2015 |pmid=25901762 |doi=10.1021/acs.jmedchem.5b00007 |pmc=4703104}}</ref>
* δ-PAM (see reference)<ref name="pmid25901762">{{cite journal |vauthors=Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, Traynor JR, Gerritz SW, Alt A |title=Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor |journal=J. Med. Chem. |volume= 58|issue= 10|pages= 4220–9|year=2015 |pmid=25901762 |doi=10.1021/acs.jmedchem.5b00007 |pmc=4703104}}</ref>
* [[Cannabidiol]]<ref name="PMID16489449">{{cite journal |vauthors=Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E | title = Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 372 | issue = 5 | pages = 354–61 | date = February 2006 | pmid = 16489449 | doi = 10.1007/s00210-006-0033-x }}</ref>
* [[Cannabidiol]]<ref name="PMID16489449">{{cite journal |vauthors=Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E | title = Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors | journal = Naunyn Schmiedebergs Arch. Pharmacol. | volume = 372 | issue = 5 | pages = 354–61 | date = February 2006 | pmid = 16489449 | doi = 10.1007/s00210-006-0033-x | s2cid = 4877869 }}</ref>
* [[Tetrahydrocannabinol]]<ref name="PMID16489449"/>
* [[Tetrahydrocannabinol]]<ref name="PMID16489449"/>
* [[Sodium]] (Na<sup>+</sup>) <ref name="pmid25073009">{{cite journal |vauthors=Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M |title=Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions |journal=Biochemistry |volume=53 |issue=31 |pages=5140–9 |year=2014 |pmid=25073009 |doi=10.1021/bi5006915 |pmc=4131901}}</ref>
* [[Sodium]] (Na<sup>+</sup>) <ref name="pmid25073009">{{cite journal |vauthors=Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M |title=Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions |journal=Biochemistry |volume=53 |issue=31 |pages=5140–9 |year=2014 |pmid=25073009 |doi=10.1021/bi5006915 |pmc=4131901}}</ref>

Revision as of 11:20, 17 September 2020

Structural correlation between met-enkephalin, an opioid peptide, (left) and morphine, an opiate drug, (right)
Main article: Opioid

An opioidergic agent (or drug) is a chemical which functions to directly modulate the opioid neuropeptide systems (i.e., endorphin, enkephalin, dynorphin, nociceptin) in the body or brain. Examples include opioid analgesics such as morphine and opioid antagonists such as naloxone. Opioidergics also comprise allosteric modulators and enzyme affecting agents like enkephalinase inhibitors.

Allosteric modulators

BMS-986121

See also

References

  1. ^ a b Burford NT, Clark MJ, Wehrman TS, et al. (June 2013). "Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor". Proc. Natl. Acad. Sci. U.S.A. 110 (26): 10830–5. doi:10.1073/pnas.1300393110. PMC 3696790. PMID 23754417.
  2. ^ Ohbuchi K, Miyagi C, Suzuki Y, Mizuhara Y, Mizuno K, Omiya Y, Yamamoto M, Warabi E, Sudo Y, Yokoyama A, Miyano K, Hirokawa T, Uezono Y (August 2016). "Ignavine: a novel allosteric modulator of the μ opioid receptor". Sci Rep. 6: 31748. doi:10.1038/srep31748. PMC 4987652. PMID 27530869.
  3. ^ Meguro Y, Miyano K, Hirayama S, et al. (May 2018). "Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator". J. Pharmacol. Sci. 137 (1): 67–75. doi:10.1016/j.jphs.2018.04.002. PMID 29716811.
  4. ^ Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, Traynor JR, Gerritz SW, Alt A (2015). "Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor". J. Med. Chem. 58 (10): 4220–9. doi:10.1021/acs.jmedchem.5b00007. PMC 4703104. PMID 25901762.
  5. ^ a b Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (February 2006). "Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors". Naunyn Schmiedebergs Arch. Pharmacol. 372 (5): 354–61. doi:10.1007/s00210-006-0033-x. PMID 16489449. S2CID 4877869.
  6. ^ Shang Y, LeRouzic V, Schneider S, Bisignano P, Pasternak GW, Filizola M (2014). "Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions". Biochemistry. 53 (31): 5140–9. doi:10.1021/bi5006915. PMC 4131901. PMID 25073009.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Opioidergic&oldid=978865022"